Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD),
including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated
median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly …

Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …

The 4th World Symposium on Pulmonary Hypertension was the first international meeting to
focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH …

Pulmonary hypertension (PH) is known to complicate various forms of interstitial lung
disease (ILD), including idiopathic pulmonary fibrosis, the interstitial pneumonias and …

Pulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients
(PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very …

RATIONALE: Pulmonary hypertension (PH) commonly complicates the course of patients
with idiopathic pulmonary fibrosis (IPF). It has a significant impact on outcomes and is …

Background Reliable, noninvasive approaches to the diagnosis of pulmonary hypertension
(PH) in patients with idiopathic pulmonary fibrosis (IPF) are needed. We tested the …

Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD).
Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in …

Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD)
patients resulting in poor functional status and worse outcomes. Early recognition of PH in …